We invested in Biorithm because maternal and fetal health remains a category where earlier visibility, better monitoring, and more accessible care can create meaningful impact. We are interested in businesses that move important healthcare functions closer to the patient while preserving clinical relevance. Biorithm reflects that model through remote monitoring that can expand access and improve continuity in pregnancy care. The company also aligns with our broader thesis around distributed diagnostics and consumer-aware care models. We believe there is durable value in products that reduce friction, extend care beyond traditional settings, and support earlier clinical action. Biorithm sits at that intersection in a category where both need and market relevance are substantial.